Amarantus Therapeutics, Inc. (“Amarantus”) is developing treatments to prevent the underlying programmed cell death (Apoptosis) associated with a wide range of devastating human diseases, including neurodegenerative and cardiovascular disorders. With a global trend towards an increasing life expectancy and emerging countries gaining access to critical medical care, there is a widespread significant unmet medical need to safely and effectively improve treatment options for the millions of patients who suffer from these devastating diseases. Amarantus’ business strategy, utilizing Amarantus’ seasoned Management Team, world-class Scientific Advisory Board, Board of Directors and Advisors, is to discover clinically relevant secreted human proteins, each with the potential to address several critically important medical indications, using our Discovery Engine for Secreted Proteins and develop them in order to address significant patient needs. The Amarantus team is using its capabilities to advance the development of high-potential therapeutic candidates and advance them through critical development stages to de-risk them and maximize their commercial potential.